Search Results
Sep 09, 2026, 11:02 ET Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis. Int J Cancer. 2025; 156(12): 2352-2359. doi:
More news about: Apeximmune
Sep 09, 2026, 08:00 ET LattePanda Launches the LattePanda Mu Ultra: A Micro x86 Compute Module for On-Device AI
Intel® Core™ Ultra 7 Processor 256V (16GB memory)AI Performance:- Up to 115 TOPS (CPU + GPU + NPU, INT8)NPU (Neural Processing Unit):- Up to 47 TOPS INT8GPU (Graphics Processing Unit):- Intel® Arc™ Graphics (up to 8 Xe Cores)Memory:-
More news about: LattePanda Team
Sep 09, 2026, 08:00 ET LattePanda Launches the LattePanda Mu Ultra: A Micro x86 Compute Module for On-Device AI
Intel® Core™ Ultra 7 Processor 256V (16GB memory)AI Performance:- Up to 115 TOPS (CPU + GPU + NPU, INT8)NPU (Neural Processing Unit):- Up to 47 TOPS INT8GPU (Graphics Processing Unit):- Intel® Arc™ Graphics (up to 8 Xe Cores)Memory:-
More news about: LattePanda Team
Sep 09, 2026, 08:00 ET LattePanda、「LattePanda Mu Ultra」を発売：オンデバイスAI向けマイクロx86コンピューティングモジュール
Ultraは、AIワークロードをデバイス上で直接実行することで、低遅延の推論、データプライバシーの向上、クラウドコンピューティングへの依存低減を可能にします。テストでは、LattePanda Mu Ultraは、iGPU上でOpenVINO GenAIを使用し、INT4量子化を適用した場合、Qwen3.5-9Bで18トークン/秒、Qwen3.5-2Bで55トークン/秒のテキスト生成速度を達成しました。これらの結果は、クラウドでの推論を必要とせず、ローカルで動作する応答性の高い会話型AIをサポートできることを示しています。このため、ローカル音声アシスタント、オフラインでの文書処理、非公開ナレッジの検索などの用途に適しており、機密データをデバイス上に保持できます。AIワークロード向け高帯域メモリLattePanda
More news about: LattePanda Team
Sep 09, 2026, 08:00 ET LattePanda führt den LattePanda Mu Ultra ein: Ein x86-Mikro-Compute-Modul für On-Device-KI
Core™ Ultra 7 Prozessor 256V (16 GB Arbeitsspeicher)KI-Leistung:- Bis zu 115 TOPS (CPU + GPU + NPU, INT8)NPU (Neural Processing Unit):- Bis zu 47 TOPS INT8--GPU (Graphics Processing Unit):- Intel® Arc™-Grafikkarte (bis zu 8 Xe-Kerne)-Speicher:-
More news about: LattePanda Team
Sep 08, 2026, 08:15 ET 禮邦醫藥 AP308 治療 IgA 腎病的新藥臨床試驗申請獲美國 FDA 批准
Shu C, Dong Y, et al. Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy. Kidney Int. 2026;110(2):463–476. doi:10.1016/j.kint.2026.04.020.[2]
More news about: 禮邦醫藥
Sep 08, 2026, 08:05 ET Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy
Shu C, Dong Y, et al. Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy. Kidney Int. 2026;110(2):463–476. doi:10.1016/j.kint.2026.04.020.[2]
More news about: Alebund Pharmaceuticals
Sep 08, 2026, 08:00 ET Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
https://hcwevents.com/annualconference/About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
https://www.nami.org/types-of-conditions/schizophrenia/Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen
More news about: Johnson & Johnson
Sep 05, 2026, 22:27 ET D-Robotics en IFA 2026: La plataforma informática que impulsa la próxima generación de robots domésticos
y los kits de desarrollo de robótica RDK™ hasta los sistemas operativos y el software de aplicación. Con una potencia que abarca de 5 a 560 TOPS* (INT8), la cartera cubre todo el espectro de la IA integrada: humanoides, cuadrúpedos, robots domésticos y de compañía, y AMR para logística.Un ecosistema
More news about: D-Robotics
Sep 05, 2026, 16:00 ET D-Robotics auf der IFA 2026: Die Rechenplattform für die nächste Generation von Heimrobotern
Sunrise™-Computing-Chips und den RDK™-Robotik-Entwicklerkits bis hin zu Betriebssystemen und Anwendungssoftware. Mit einem Leistungsspektrum von 5 bis 560 TOPS* (INT8) deckt das Portfolio das gesamte Spektrum der verkörperten KI ab: Humanoide, Vierbeiner, Haushalts- und Begleitroboter sowie AMRs für die Logistik.Ein
More news about: D-Robotics
Sep 05, 2026, 15:57 ET D-Robotics à l'IFA 2026 : la plateforme informatique au cœur de la prochaine génération de robots domestiques
les kits de développement robotique RDK™ jusqu'aux systèmes d'exploitation et aux logiciels d'application. Avec une gamme allant de 5 à 560 TOPS* (INT8), ce portefeuille couvre une gamme complète de solutions d'IA embarquée : les humanoïdes, les quadrupèdes, les robots domestiques et compagnons, ainsi
More news about: D-Robotics
Sep 04, 2026, 03:00 ET D-Robotics at IFA 2026: The Computing Platform Powering the Next Generation of Home Robots
from Sunrise™ intelligent computing chips and RDK™ robotics developer kits to operating systems and application software. Spanning 5 to 560 TOPS* (INT8), the portfolio covers the full spectrum of embodied AI: humanoids, quadrupeds, home service and companion robots, and logistics AMRs.An ecosystem
More news about: D-Robotics
Sep 02, 2026, 10:46 ET ST Engineering iDirect Demonstrates Multi-Waveform 5G NR-NTN User Equipment Pilot
communications, today demonstrated a pilot version of the INT3000, its multi-waveform 5G New Radio Non-Terrestrial Network (NR-NTN) User Equipment (UE) modem, at the European Space Agency (ESA) 5G NTN Forum. The INT3000 is being developed to support both 5G NR NTN and DVB-S2X/MRC waveforms in a single device,
More news about: ST Engineering iDirect
Sep 02, 2026, 10:46 ET ST Engineering iDirect Demonstrates Multi-Waveform 5G NR-NTN User Equipment Pilot
communications, today demonstrated a pilot version of the INT3000, its multi-waveform 5G New Radio Non-Terrestrial Network (NR-NTN) User Equipment (UE) modem, at the European Space Agency (ESA) 5G NTN Forum. The INT3000 is being developed to support both 5G NR NTN and DVB-S2X/MRC waveforms in a single device,
More news about: ST Engineering iDirect
Aug 26, 2026, 06:47 ET Alebund Pharmaceuticals Announces 2026 Interim Results
disease. Kidney Int Rep. Published online August 20, 2026. doi:10.1016/j.ekir.2026.107037[2] Shen X, et al. Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy. Kidney Int. 2026;110:463–476. doi:10.1016/j.kint.2026.04.020About Alebund
More news about: Alebund Pharmaceuticals
Aug 26, 2026, 06:44 ET 禮邦醫藥發佈 2026 年中期業績
disease. Kidney Int Rep. Published online August 20, 2026. doi:10.1016/j.ekir.2026.107037[2] Shen X, et al. Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy. Kidney Int. 2026;110:463–476. doi:10.1016/j.kint.2026.04.020
More news about: 禮邦醫藥
Aug 24, 2026, 17:41 ET BreakBio, the Third Player in Personalized Drugs, Enters the Clinic
Personalized Drugs, Enters the ClinicBreakBio is designed for higher efficacy than Moderna's individualized neoantigen therapy (INT). Higher efficacy because BreakBio is designed to find better targets per patient. It is an AI first biotech company. For every patient, its platform
More news about: BreakBio Corp.
Aug 24, 2026, 15:17 ET Current Standardizes Its $600M Firm Network on a Single Platform
accounting profession for the next century.Media ContactsCurrentLisa Hillmer‑PooleSVP, Brand Strat & Int [email protected]
More news about: Aiwyn; Current
Aug 24, 2026, 08:00 ET LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Aug 19, 2026, 08:30 ET New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
PMCID: PMC6056063. Cheng S, Lin D, Hu T, et al. Association of urinary incontinence and depression or anxiety: a meta‑analysis. J Int Med Res. 2020;48(6):0300060520931348. doi: 10.1177/0300060520931348. PMID: 32552169; PMCID: PMC7303787.National Association for Continence.
More news about: Wellspect HealthCare
Aug 11, 2026, 09:00 ET Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
Rooney MR, et al. Diabetologia. 2025 Feb;68(2):357-366. Cancers: Huang Y, et al. Diabetologia. 2014 Nov;57(11):2261-9. AD + dementia: Ezkurdia A, et al. Int J Mol Sci. 2023 Feb 22;24(5):4354.1
More news about: Abbott
Aug 11, 2026, 08:00 ET Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
427-434;[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.[3] de Serres FJ, Blanco I, Fernández-Bustillo E. Estimating the risk for alpha-1 antitrypsin
More news about: Sentynl Therapeutics
Aug 11, 2026, 07:30 ET Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Aug 07, 2026, 07:02 ET 禮邦醫藥AP301新藥上市申請獲國家藥監局受理
[1] CIC《全球及中國高磷血症藥物行業藍皮書》，2023年[2] KDIGO 2017 Clinical Practice Guideline Update. Kidney Int Suppl. 2017;7(1):1–59.[3] Guedes M, et al. Kidney Med. 2023;5(2):100584. doi:10.1016/j.xkme.2022.100584.[4] Zuo
More news about: 禮邦醫藥